Key Takeaways
- Steady margin improvement, clean quarter: Operating profit margin improved sequentially in both value and percentage, driven by better product mix, favorable IPI prices, and forex gains on exports.
- Diabetes portfolio consolidation is working: Integrating all anti-diabetes products under one business unit eliminated duplicated efforts, expanded reach, and strengthened brand positioning, creating a platform to follow the patient journey end-to-end.
- Lantus poised for share gains post-NLEM: The price gap between Lantus and competitors has shrunk to near zero after NLEM implementation, and Q4 volume growth of ~5% signals a positive trajectory for pulling additional market share.
- Soliqua launch opens a large adjacent market: Entering the pre-mix insulin segment, which is as large as the basal segment in India, with a differentiated product offering fewer injections, lower hypoglycemia risk, and weight management advantages.
- What to watch next quarter: Soliqua launch execution by early Q2, the pace of Lantus volume growth sustaining above Q4 levels, and any disclosure around the CATD merger separation readiness.
Diabetes Portfolio & Insulin Strategy
- Consolidated business unit: All anti-diabetes products now sit under one specialized leadership team, replacing a structure where products were split across two business units with duplicated efforts. The integration expands reach and allows the company to follow the patient and HCP journey from oral drugs through to insulin.
- Lantus NLEM tailwind: After NLEM price reduction on Lantus, insulin prescriptions increased significantly as HCPs opted for it more. The price difference versus competitors has shrunk to close to zero, which management expects will pull more market share going forward.
- One-off prescription headwind in 2023: Loss of exclusivity on certain oral anti-diabetic products reduced their prices and caused a delay in insulinization of patients, shrinking the overall market pie temporarily even though Sanofi's share of prescriptions increased significantly.
- Toujeo migration story intact: Toujeo continues to grow on the back of migration to second-generation basal insulin, with the market showing appetite for more sophisticated options in both basal and pre-mix segments.
- Soliqua targets the pre-mix segment: India has a developed pre-mix insulin category comparable in size and growth rate to the basal segment, driven by delayed insulinization and carbohydrate-heavy diets. Soliqua enters as a unique product with clear differentiation.
- Insuman localized: Formerly imported, Insuman is now manufactured locally, which could improve cost competitiveness and support growth.
Rodolfo Hrosz: "The brand has gone very fast. It's a second-generation basal insulin and we've seen that the market has an appetite for second generation, both in basal and also in the premium segment. So Lantus continues to grow on the wake of the NLEM price reduction and Toujeo continues to grow on the waves of this migration to second generation and more sophisticated basal insulin. So both have a very promising perspective and in fact both are performing well on their side, in their segment."
Consumer Healthcare Performance
- Market share gains despite category headwinds: All categories and all brands continued gaining market share in Q4, with Allegra, Dulcoflex, and Depura gaining significantly, even as the overall category faced headwinds. Strong performance has continued into January.
- Leadership transition underway: Himanshu Bakshi joined as General Manager of Consumer Healthcare on 15th January 2024 and will transition to Managing Director of Sanofi Consumer Healthcare India Limited post-merger, subject to approvals.
- Allegra introduction planned for 2025: The company is well advanced in planning for the Allegra launch, with C&C (contract manufacturing and commercialization) arrangements in place.
Himanshu Bakshi: "When we look at quarter 4. Of course, there are some headwinds when it comes to the overall category performance. But the good news is that all our categories, all our brands continue to gain share in the market."
Product Launches & Pipeline
- Recent launches: Freezing suspension launched in October 2023; Sanoxaban and Carmada (line extensions of existing brands) launched mid-December 2023, with no material contribution yet in the quarter.
- Near-term pipeline: Soliqua launch targeted for end of Q1 or beginning of Q2; Cetapin S (local extension) planned for end of Q1; Insutage (localized insulin) introduction planned soon.
- Line extension philosophy: Extensions are carefully selected to tap segments where Sanofi is not currently playing, minimizing cannibalization of existing brands.
- Amaryl resilience: Amaryl remains very strong and solid, not shaken by loss of exclusivity events on dapagliflozin or gliptins.
- R&D capability in Goa: Sanofi has one of the most sophisticated R&D centers of the Sanofi Group located in Goa, and the challenge is to leverage that installed capability as the pipeline is built.
CATD Merger & Structural Changes
- Merger on track for Q2 execution: Both regulatory approvals received, shareholders approved by December 18th, and organizational readiness for separation is well advanced.
- Opex savings from prior restructuring: INR 36 crores in opex savings achieved in FY23 by reducing eight business units to three, removing one management layer, deploying the trade organization, and piloting four digital go-to-market organizations.
- Dividend payout reduced to 65%: Down from 85% last year, explained by working capital build-up of stock at year-end to avoid disruption from a warehouse address change, license re-approval, and a blackout period.
Exports & Manufacturing
- Export expansion underway: The company is looking to export to Russia and Central Asia while continuing with current markets supplied from Goa. Volume increases will allow future cost reduction as capacity utilization rises at the Goa site.
- Goa site validated: The Goa site and contract manufacturing organizations are validated and vetted by quality and supply chain organizations.
- Insuman localization complete: A formerly imported insulin is now produced in India, potentially helping cost competitiveness.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Soliqua launch | Enter the pre-mix insulin segment with a differentiated product | End of Q1 / beginning of Q2 FY25 |
| Cetapin S launch | Local extension of existing brand | End of Q1 FY25 |
| CATD merger execution | Complete separation of consumer healthcare business | Q2 FY25 |
| Allegra introduction | Launch in consumer healthcare portfolio | By 2025 |
| Lantus market share | Pull additional share as price gap versus competitors has shrunk to near zero | Ongoing, supported by Q4 volume growth of ~5% |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹525 cr, 12.6% growth as published, 10.6% comparable excluding NLEM price impact |
| Profit before tax growth | +5.6%, excluding Soframycin divestment |
| Operating profit margin | 31%, up from 27% in Q3 FY23 |
| Full-year revenue growth (comparable) | 5.4%, 1.2% as published |
| Full-year export growth | +27% |
| Full-year opex change | -6% |
| Full-year profit before tax margin | 31%, up from 26% in FY22 |
| Dividend payout ratio | 65%, down from 85% last year, due to working capital build for warehouse address change |
| Diabetes portfolio EBIT contribution | 40% to 43% |
| Share of revenue under NLEM | 39% to 40% |
| Exports as share of total top line | 18% to 20% |
| Goa plant export share | ~30% |
| Lantus Q4 volume growth | ~5% |
| Opex savings from restructuring | ₹36 cr in fiscal year 2023 |
| Diabetes awareness campaign reach | >20 crore people in 2023 |